Cinacalcet-associated cardiogenic shock in a patient with cardiomyopathy.
BACKGROUND
Cinacalcet is a calcimimtic agent used to treat secondary hyperparathyroidism in patients with end-stage renal disease on dialysis or hypercalcemia related to parathyroid carcinoma. This report describes recurring circulatory collapse in a patient treated with cinacalcet for unrelated refractory primary hyperparathyroidism.


METHODS
A white man, aged 54 years and weighing 68 kg, was admitted to the hospital with lethargy, dyspnea, and twitching in the extremities. He was diagnosed previously with primary hyperparathyroidism and nonischemic dilated cardiomyopathy. Surgical parathyroidectomy had been unsuccessful. His serum calcium concentration was 3.15 micromol/L and was refractory to bisphosphonate therapy. Therapy with cinacalcet 30 mg/d was reinitiated, resulting in a reduction in serum calcium concentration and greatly increased heart failure requiring inotropic drug therapy and hemofiltration. After 13 days of treatment, cinacalcet was withdrawn, and the patient's condition unproved. On reintroduction of cinacalcet 30 mg/d, the patient decompensated and required emergency circulatory support. Decompensation resolved 5 days after discontinuation of cinacalcet.


CONCLUSIONS
Based on a score of 7 on the Naranjo adverse drug reaction probability scale, cinacalcet was the probable cause of cardiogenic shock in this patient. Calcium-channel antagonist poisoning is associated with hypotension and bradycardia, whereas the calcium sensitizer levosimendan has been reported to improve low-output heart failure, suggesting that calcium may have inotropic properties.


CONCLUSIONS
It appears that cardiac function in this patient had adapted to hypercalcemia and became destabilized after introduction of cinacalcet. Caution should be exercised when considering treatment with cinacalcet in patients with heart failure.
Tilling
Lindsey
L
John Radcli ffe Hospital, Oxford, United Kingdom. lindseytilling@hotmail.com <lindseytilling@hotmail.com>
Colin Forfar
J
J
D002118:Calcium / Q000097:blood; D009202:Cardiomyopathies / Q000150:complications*; D002316:Cardiotonic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000069449:Cinacalcet; D004334:Drug Administration Schedule; D006333:Heart Failure / Q000139:chemically induced; D006440:Hemofiltration; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy*; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000009:adverse effects* / Q000627:therapeutic use; D011336:Probability; D012770:Shock, Cardiogenic / Q000139:chemically induced*
D002316:Cardiotonic Agents; D009281:Naphthalenes; D002118:Calcium; D000069449:Cinacalcet